Bruker (NASDAQ:BRKR) Issues FY 2024 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.360-2.410 for the period, compared to the consensus EPS estimate of 3.590. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.4 billion. Bruker also updated its FY24 guidance to $2.36-2.41 EPS.

Bruker Stock Down 2.7 %

BRKR traded down $1.67 during trading on Wednesday, hitting $59.67. 1,162,502 shares of the company’s stock were exchanged, compared to its average volume of 1,067,669. Bruker has a fifty-two week low of $54.55 and a fifty-two week high of $94.86. The stock has a market cap of $9.03 billion, a P/E ratio of 24.98, a PEG ratio of 2.32 and a beta of 1.20. The business’s 50 day moving average is $64.08 and its two-hundred day moving average is $66.56. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the prior year, the company earned $0.74 EPS. The company’s revenue was up 16.4% on a year-over-year basis. As a group, equities analysts expect that Bruker will post 2.61 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend was Friday, August 30th. Bruker’s payout ratio is 8.30%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BRKR shares. Citigroup decreased their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday. The Goldman Sachs Group lowered their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. TD Cowen decreased their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday. Finally, Barclays dropped their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average target price of $79.36.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.